Skip to content

#Regulator decision

14 NovSat
  1. The Microdose (UC Berkeley BCSP)62

    FDA said to end priority voucher program as Compass Pathways files psilocybin application

    Reuters reported that the US Food and Drug Administration is ending the Commissioner's National Priority Voucher program, which had compressed a 10-12 month drug review to 1-2 months. Three psychedelics-related voucher holders are affected, including Compass Pathways' COMP360 for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder and Transcend Therapeutics' methylone for PTSD.

2 NovMon
22 OctThu
30 SepWed
  1. MAPS62

    MAPS opposes DEA proposal to place five tryptamines in Schedule I

    MAPS has stated its opposition to a DEA proposal to place five little-known psychedelic compounds, 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT, in Schedule I of the Controlled Substances Act. The organisation says this is the agency's second attempt at the same scheduling action, after an earlier version was withdrawn in 2022 following pushback from researchers and legal advocates.

28 MayThu
24 MaySun
  1. TGA: final scheduling decisions (Australia)62

    TGA publishes final Poisons Standard decisions from ACCS #40 and Joint ACMS-ACCS #39

    The TGA has published its notice of final decisions on whether to amend the Poisons Standard, following the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The publication is issued under regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990. The feed supplied only a summary, so the specific substances and outcomes are not stated here.

    Why it matters: The notice is the formal record of which scheduling proposals were accepted or rejected, so companies and prescribers can check whether a compound's legal status changed.

28 JanWed